Royal Bank Of Canada Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Equities research analysts at Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report released on Friday. The firm set an “outperform” rating and a $40.00 price target on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 57.36% from the company’s previous close.

DMRA has been the subject of a number of other reports. Guggenheim restated a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Leerink Partners began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price objective for the company. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th. Finally, Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $43.40.

Damora Therapeutics, Inc. Common Stock Trading Down 1.9%

DMRA opened at $25.42 on Friday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The company has a market cap of $1.53 billion, a P/E ratio of -2.10 and a beta of 1.59. The business’s 50-day moving average price is $27.13 and its 200-day moving average price is $22.61.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $40,000. Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $76,000. Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $100,000. Boothbay Fund Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $2,204,000. Finally, Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $2,772,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.